Galectin Converts $105.8M in Debt to Equity
Chairman Richard E. Uihlein converted $105.8 million in outstanding debt into 34.4 million common shares, significantly strengthening the biopharmaceutical company's balance sheet.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day